New Practice Model May Reduce Miscarriage
Reports new study in Reproductive BioMedicine Online
Reports new study in Reproductive BioMedicine Online
Amsterdam, January 5, 2011 – Elsevier, a world-leading provider of scientific, technical and medical information products and services today announced the publication of an article in the December issue of Reproductive BioMedicine Online (www.rbmonline.com) about miscarriage rates following IVF treatment with frozen thawed embryos which may revolutionize clinical and laboratory practice.
As the practice of freezing and transferring ‘surplus’ embryos widens rapidly, concerns about whether the freezing process may interfere with the viability of the embryos are often raised by patients. The study highlights that miscarriage is less likely to occur after the transfer of fresh embryos compared with frozen-thawed embryos, but also that the age of the embryos at the time of freezing could influence the miscarriage rate.
Y.A. Wang and colleagues undertook a retrospective analysis of 52,874 clinical pregnancies recorded on the Australian and New Zealand Assisted Reproduction Database (ANZARD) between 2004 and 2008 that showed that the woman’s age and obstetric history are closely related to the risk of miscarriage, and that the transfer of fresh embryos is associated with fewer miscarriages than transfer of frozen–thawed embryos.
The overall miscarriage rate was 18.7%; younger women (< 35 years) being almost 3 times less likely to miscarry than women > 40 years of age, and women who had an elective single embryo transfer were less likely to miscarry than if two embryos were transferred. Transferring thawed embryos which were frozen at an earlier stage of development than the blastocyst were less likely to miscarry. The authors proposed a practice model of transferring fresh blastocysts and freezing of cleavage-stage embryos to reduce the miscarriage rate after IVF and related treatments. Such a model, they claim, could lead to a substantial reduction in the miscarriage rate and eliminate much of the anxiety suffered by women undergoing Assisted Reproductive Technology.
As noted by Yacoub Khalaf, Director of the Assisted Conception Unit at Guy’s and St Thomas’ NHS Foundation Trust, London, in a commentary in the same issue of Reproductive BioMedicine Online, this model may have practical limitations and would need validation in a randomized trial. Large databases aggregated over many years are not free of bias and are not usually comprehensive enough to account for all the pertinent variables. Retrospective analysis of large national databases is useful in identifying trends and generating hypothesis, but evaluation of these hypotheses in randomized trials remains necessary for objective validation.
"It is interesting that miscarriage rates of frozen blastocysts were higher in the Australian study, particularly since it is well known that blastocysts have a lower frequency of chromosomal anomalies than cleaved embryos. Blastocyst culture is still a relatively new approach and culture-related factors such as selection for freezing at blastocyst stage may have affected early learning experiences in some clinics. It is therefore important to repeat a similar analysis of Australian clinic data during subsequent years," Dr. Jacques Cohen, senior editor of Reproductive BioMedicine Online, said of the study.
The article is “Transfers of fresh blastocysts and blastocysts cultured from thawed cleavage embryos are associated with fewer miscarriages” by Yueping Alex Wang, Michael Costello, Michael Chapman, Deborah Black, Elizabeth Anne Sullivan ( doi:10.1016/j.rbmo.2011.07.023). The article appears in Reproductive BioMedicine Online, Volume 23, Issue 6 (December, 2011), published by Elsevier.
The commentary is “The search for a practice model to reduce miscarriage after assisted reproduction” by Yakoub Khalaf, Tarek El-Toukhy(doi:10.1016/j.rbmo.2011.09.014). The commentary appears in Reproductive BioMedicine Online, Volume 23, Issue 6 (December, 2011), published by Elsevier.
# # #
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Greyling Peoples at +31 20 485 3323 or email@example.com. Journalists wishing to interview the authors may contact Alex Wang at firstname.lastname@example.org.
Reproductive BioMedicine Online was founded by Bob Edwards, the winner of the 2010 Nobel Prize in Physiology or Medicine. It covers the formation, growth and differentiation of the human embryo. It is intended to bring to public attention new research on biological and clinical research on human reproduction and the human embryo including relevant studies on animals. It is published by a group of scientists and clinicians working in these fields of study. Its audience comprises researchers, clinicians, practitioners, academics and patients. It is the Official journal of Alpha (Scientists in Reproductive Medicine), American College of Embryology (ACE), the Global Chinese Association for Reproductive Medicine (GCARM), International Society for Fallopian Tubes and Reproductive Surgery (ISFT-RS),the International Society for In Vitro Fertilization (ISIVF), the Mediterranean Society for Reproductive Medicine (MSRM), the Preimplantation Genetic Diagnosis International Society (PGDIS) and the Turkish Society of Reproductive Medicine (TSRM).
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com
+31 20 485 3323